Sun Pharmaceutical Industries Limited — Updates, 30-05-2025: Press Release

Sun Pharma has announced a board meeting on the financial results for the quarter and half-year. The company completed the acquisition of Checkpoint Therapeutics, adding UNLOXCYT™, the first FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma. This strengthens Sun Pharma’s oncology portfolio and onco-derm leadership. The deal was executed at $4.10 per share plus contingent value rights up to $0.70 per share, enhancing its innovative therapies segment and expanding targeted cancer treatment access.